标题：Research Grade Vatreptacog alfa对照抗体,AntibodySystem Laboratories
链接：https://www.antibodysystem.com/product/19169.html
名称：Research Grade Vatreptacog alfa对照抗体
别名：rFVIIa analog NN1731, FVIIa DVQ, Eptacog Alfa
货号：DHC35901
适用物种：Human
存储缓冲区：0.01M PBS, pH 7.4.
浓度：1 mg/ml
形式：Liquid
纯度：>95%
克隆：Monoclonal
同型：A recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions (Asp158Val, Val296Glu, and Glu298Met).
应用：Research Grade Biosimilar
靶点：F7, Proconvertin, SPCA, Serum prothrombin conversion accelerator, Coagulation factor VII, Eptacog alfa
内毒素水平：Please contact with the lab for this information.
UniProt：P08709
用途范围：仅用于科研
储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
参考文献：
Vatreptacog alfa from conception to clinical proof of concept. PMID: 22510860
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. PMID: 22470921
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. PMID: 26362483
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. PMID: 24931322
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. PMID: 21681082
The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity. PMID: 37915568
Hemostatic properties of the FVIIa analog NN1731. PMID: 22446168
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. PMID: 31506285
Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia. PMID: 22757678
Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. PMID: 28077675
The effect of acylation with fatty acids and other modifications on HLA class II:peptide binding and T cell stimulation for three model peptides. PMID: 29758051
